Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.006.82%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.77% | 11.16% | 27.73% | -59.14% | 51.84% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.64% | -4.93% | 5.15% | -2.94% | -75.79% |
| Change in Net Operating Assets | 39,156.25% | -101.01% | -84.02% | 482.90% | -235.49% |
| Cash from Operations | 58.88% | -3.54% | -60.56% | 52.16% | -19.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -65.99% | 85.85% | -1.85% | 18.68% | -17.27% |
| Total Debt Repaid | 7.72% | -154.55% | 51.42% | 14.29% | -32.95% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -50.00% | -- | -- | -100.00% | 133.33% |
| Cash from Financing | -68.53% | 111.37% | 5.56% | -56.22% | 36.11% |
| Foreign Exchange rate Adjustments | 200.00% | -- | -100.00% | 300.00% | 111.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.32% | 151.98% | -549.06% | -161.08% | 83.69% |